The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to $8.49 billion.

Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market.

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance ...

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer ...

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and ...

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

The next 10 months might be challenging for this biotech.

Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay ...

Biotech picks highlight cystic fibrosis drug trials, rare-disease therapies and upcoming regulatory catalysts as clinical ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going ...